Eventide Asset Management ALNY Position
Active10-Fund ConvergenceEventide Asset Management trimmed their position in Alnylam Pharmaceuticals Inc. (ALNY) in Q4 2025, holding $13.5M worth of shares across 34,035 shares.
The position was first reported in Q4 2023 and has been tracked across 9 quarterly 13F filings.
ALNY is a convergence signal: 10 specialist biotech funds hold this stock, suggesting high institutional conviction.
There is an upcoming Phase 2 readout for ALN-4324 in 407 days (May 28, 2027), making the timing of Eventide's position particularly relevant.
About Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals, Inc., a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. The company's pipeline of investigational RNAi therapeutics focuses on genetic medicines, cardio-metabolic diseases, hepatic infectious diseases, and central nervous system (CNS)/ocular diseases. Its marketed products include ONPATTRO (patisiran), a lipid complex injection for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria (AHP); and OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). In addition, the company is developing givosiran for the treatment of adolescent patients with AHP; patisiran for the treatment of transthyretin amyloidosis, or ATTR amyloidosis, with cardiomyopathy; cemdisiran to treat complement-mediated diseases; ALN-AAT02 for the treatment of AAT deficiency-associated liver disease; ALN-HBV02 to treat chronic HBV infection; Zilebesiran to treat hypertension; and ALN-HSD to treat NASH. Further, it offers Fitusiran for the treatment of hemophilia and rare bleeding disorders, Inclisiran to treat hypercholesterolemia, lumasiran for the treatment of advanced PH1 and recurrent renal stones, and vutrisiran for the treatment of ATTR amyloidosis, which is in phase 3 clinical trial. Alnylam Pharmaceuticals, Inc. has strategic collaborations with Regeneron Pharmaceuticals, Inc. to discover, develop, and commercialize RNAi therapeutics for a range of diseases by addressing therapeutic targets expressed in the eye and CNS; and Sanofi Genzyme to discover, develop, and commercialize RNAi therapeutics. It also has license and collaboration agreements with Novartis AG; Vir Biotechnology, Inc.; Dicerna Pharmaceuticals, Inc.; Ionis Pharmaceuticals, Inc.; and PeptiDream, Inc. The company was founded in 2002 and is headquartered in Cambridge, Massachusetts.
Full company profile →Short Interest
4.3%
4.2 days to cover
Eventide Asset Management ALNY Position History
| Quarter | Action | Shares | Change | Value |
|---|---|---|---|---|
| Q4 2025 | Decreased | 34,035 | -67,704 | $13.5M |
| Q3 2025 | Decreased | 101,739 | -24,163 | $46.4M |
| Q2 2025 | Decreased | 125,902 | -40,548 | $41.1M |
| Q1 2025 | Decreased | 166,450 | -73,968 | $44.9M |
| Q4 2024 | Increased | 240,418 | +16,085 | $56.6M |
| Q3 2024 | Increased | 224,333 | +137,333 | $61.7M |
| Q2 2024 | Held | 87,000 | — | $21.1M |
| Q1 2024 | Held | 87,000 | — | $13.0M |
| Q4 2023 | New | 87,000 | +87,000 | $16.7M |
Frequently Asked Questions
Does Eventide Asset Management own ALNY?
Yes. As of Q4 2025, Eventide Asset Management holds 34,035 shares of Alnylam Pharmaceuticals Inc. (ALNY) valued at $13.5M. This data comes from their SEC 13F filing.
How many hedge funds own ALNY?
10 specialist biotech hedge funds currently hold ALNY, including RTW Investments, Avoro Capital Advisors, OrbiMed Advisors and 6 more. When 3 or more specialist funds hold the same stock, BiotechEdge flags it as a convergence signal.
When did Eventide Asset Management first buy ALNY?
Eventide Asset Management's position in ALNY was first reported in Q4 2023. 13F filings are reported with a 45-day delay, so the actual purchase may have occurred earlier in the quarter.
Is Eventide Asset Management's ALNY position increasing or decreasing?
Eventide Asset Management trimmed their ALNY position in the most recent quarter, reducing by 67,704 shares.
Get the weekly biotech signal briefing
Fund moves, convergence shifts, insider buys, and catalyst alerts — delivered free every Monday.
ALNYCompany Page →
All fund holders, insider trades, catalysts, and cash runway
Eventide Asset ManagementPortfolio →
Full 13F holdings, sector breakdown, and top movers
Drill into any signal
Fund Convergence
See which stocks multiple specialist funds are buying at once
Catalyst Calendar
Every PDUFA date, Phase 3 readout, and AdCom in one view
Insider Trading
When executives buy their own stock — the strongest bullish signal
Cash Runway
Which biotechs are running low on cash and face dilution risk
Short Squeeze
High short interest + fund buying + upcoming catalyst = squeeze setup
Signal Rankings
Every signal in one composite score — ranked by conviction
Biotech Movers
Stocks with the most signal activity right now across all signals
13F Changes
What top biotech funds bought and sold in the latest 13F filing
Want AI context on every signal? Start free trial →